US2014296145A1PendingUtilityA1

Modified Human Growth Hormone Polypeptides and Their Uses

Assignee: AMBRX INCPriority: Feb 2, 2004Filed: Apr 2, 2014Published: Oct 2, 2014
Est. expiryFeb 2, 2024(expired)· nominal 20-yr term from priority
A61P 5/06A61P 5/12A61P 7/06A61P 37/04A61P 5/00A61P 9/00A61P 5/10A61P 37/02A61P 3/10A61P 43/00A61P 35/00A61P 31/12A61P 35/02A61P 27/02A61P 25/00A61P 29/00A61P 31/18G01N 2500/00A61P 1/16C07H 21/04C07K 14/475C07K 14/61A61K 38/21C08G 65/33396C07K 14/52A61K 38/27A61K 47/60G01N 33/6875A61P 13/08A61P 13/12C07K 14/575C07K 14/555C07K 14/53C07K 14/505C07K 14/435A61K 38/193A61K 38/1808A61K 38/16A61K 38/17A61K 47/48215
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Modified human growth hormone polypeptides and uses thereof are provided.

Claims

exact text as granted — not AI-modified
1 - 100 . (canceled) 
     
     
         101 . A pharmaceutical formulation of a human growth hormone (hGH) variant comprising one or more non-naturally encoded amino acids wherein the non-naturally encoded amino acids are substituted at positions selected from the group consisting of 35, 92, 131, 134, 143 and 145 of SEQ ID NO: 2 and the non-naturally encoded amino acids have the structure: 
       
         
           
           
               
               
           
         
         wherein R3 is any substituent other than one used in the twenty natural amino acids; 
         wherein each of R1 and R2 is one or more amino acids; and 
         wherein each non-naturally encoded amino acid is linked to a water soluble polymer and wherein the serum half-life of the linked variant is at least two-fold greater than the serum half-life of a wild type hGH protein and wherein said formulation has a concentration between 8 mg/mL and 14 mg/mL. 
       
     
     
         102 . A pharmaceutical formulation of a human growth hormone (hGH) variant comprising one or more non-naturally encoded amino acids wherein the non-naturally encoded amino acids are substituted at positions selected from the group consisting of 35, 92, 131, 134, 143 and 145 of SEQ ID NO: 2 and the non-naturally encoded amino acids have the structure: 
       
         
           
           
               
               
           
         
         wherein R3 is any substituent other than one used in the twenty natural amino acids; 
         wherein each of R1 and R2 is one or more amino acids; and 
         wherein each non-naturally encoded amino acid is linked to a water soluble polymer, and wherein the serum half-life of the linked variant is at least two-fold greater than the serum half-life of a wild type hGH protein and wherein said formulation has a concentration between 8 mg/mL and 10 mg/mL and said formulation's viscosity allows for 1 mL to be injected through a 27 gauge needle with 4 lbs of force in 5 seconds or less.

Join the waitlist — get patent alerts

Track US2014296145A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.